Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of senior management will participate in two investor conferences in June.

Conference Details:

Event: Jefferies Global Healthcare Conference Details: Michael Howell, Ph.D., Chief Scientific Officer and Head of Translational Medicine, will participate in one-on-one meetings on Thursday, June 6, 2024, in New York, NY.

Event: Oppenheimer Novel Targets in Immunology Summit Details: Robert Lisicki, Chief Executive Officer, will participate in a “Novel Immunological Mechanisms for Dermatological Disorders” panel discussion and one-on-one meetings on Monday, June 24, 2024, in New York, NY.

ABOUT ZURA BIO

Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880), with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs.

Megan K. Weinshank Head of Investor Relations ir@zurabio.com

Lee M. Stern Meru Advisors lstern@meruadvisors.com

Zura Bio (NASDAQ:ZURA)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Zura Bio Charts.
Zura Bio (NASDAQ:ZURA)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Zura Bio Charts.